Is actemra iv or sq?

Is Actemra IV or SQ?

Actemra is available in both intravenous (IV) and subcutaneous (SQ) formulations. The IV form requires administration by a healthcare provider every four weeks, while the SQ form is designed for self-injection every one or two weeks.

How does the choice between IV and SQ affect dosing frequency?

The IV version is given once every four weeks at a weight-based dose. The SQ version allows patients to inject themselves at home, with a fixed dose for patients under 100 kg (162 mg weekly) or a biweekly schedule for those who are heavier.

What conditions is Actemra approved for in each form?

Both forms are approved for rheumatoid arthritis. The IV version is also approved for giant cell arteritis, systemic juvenile idiopathic arthritis, and polyarticular juvenile idiopathic arthritis. The SQ version is approved for giant cell arteritis and polyarticular juvenile idiopathic arthritis.

When does Actemra patent expire?

The compound patent for tocilizumab expired in 2023. The formulation patents for the IV version expired in 2021. The SQ formulation is still protected by patents that may extend through 2030.